The Sound of Evolution
Basiliximab
Mechanism of action:
Basiliximab is a chimeric monoclonal antibody. It specifically binds to the interleukin-2 receptor α chain (IL-2R α chain, also known as CD25) on the surface of T cells, a receptor expressed only on activated T cells. This blocks the binding of IL-2 to its receptor, thereby inhibiting T cell activation and proliferation and preventing the expansion of activated T cells and their immune attack against transplanted organs.
Reference(s):
1. Onrust SV et al. (1999). Basiliximab. Drugs.
2. Hausen B et al. (2000). Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation.